When we think about iron imbalance, most people are familiar with iron deficiency and the health problems it can cause. What ...

Convicted sex offender Jeffrey Epstein paid for genetic testing in an apparent bid to harness his own genetic material for regenerative medicine – which is aimed at repairing the body by developing ...

With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...

Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...

NCCN's newly updated NSCLC guidelines add sevabertinib as a treatment option and datopotamab deruxtecan-dlink a potential preferred option.

The CHMP decision is based on Phase III AMPLITUDE study results in 696 mHSPC patients.

The trial will include patients with pancreatic, colorectal, non-small cell lung, and other cancers that harbor KRAS G12V mutations.

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...

Pancreatic cancer remains one of the deadliest cancers known, but two independent experimental therapies have now ...

In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.

The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and ...